A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Boehringer Ingelheim
Montefiore Medical Center
Nammi Therapeutics Inc
Revolution Medicines, Inc.
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Brigham and Women's Hospital
Indiana University
Abramson Cancer Center at Penn Medicine
Replimune, Inc.
Cancer Research UK
Carevive Systems, Inc.
Revolution Medicines, Inc.
DualityBio Inc.
Lumicell, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
I-Mab Biopharma US Limited
Shanghai Juncell Therapeutics
BicycleTx Limited
City of Hope Medical Center
Revolution Medicines, Inc.
British Columbia Cancer Agency
Bolt Biotherapeutics, Inc.
Revolution Medicines, Inc.
Marengo Therapeutics, Inc.
City of Hope Medical Center
NRG Oncology
Hoffmann-La Roche
Revolution Medicines, Inc.
Cedars-Sinai Medical Center
Kantonsspital Winterthur KSW
University of Chicago
Baylor College of Medicine
Celldex Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Dartmouth-Hitchcock Medical Center
University Hospital, Ghent
M.D. Anderson Cancer Center
Fondazione per la Medicina Personalizzata
University of Rochester
Hoffmann-La Roche
Massachusetts General Hospital
Shanghai Yunying Medical Technology